Enzyvant Announces Plans to Expand Regenerative Medicine Manufacturing Capabilities

Enzyvant, a commercial-stage biotechnology company with a focus on regenerative medicines for rare diseases, announced today plans to develop a Good Manufacturing Practice (GMP)-compliant regenerative medicine manufacturing facility in Morrisville, NC, part of the Research Triangle Park area.

“Enzyvant is committed to ensuring scalable GMP manufacturing for RETHYMIC (allogeneic processed thymus tissue-agdc), and we’re looking ahead to potential needs in other indications and in support of other advanced regenerative medicine technologies,” said Enzyvant CEO William Symonds. “This new facility, once completed, will give us the size, flexibility, and nimble processing capability to serve both commercial and research needs.”

The development of the 25,972-square-foot facility is expected to begin this summer and take approximately two and a half years to complete once construction begins. Enzyvant currently has research and development offices in Durham, NC.

“I am very pleased about the novel capabilities this new manufacturing facility will bring to Enzyvant and look forward to the progress ahead as we look to realize efforts,” said Myrtle Potter, CEO of Sumitovant. “This is a great example of three members of the Sumitomo Pharma family of companies working seamlessly together to address the most pressing issues affecting patients and families with the highest unmet medical needs.”

The new manufacturing facility is being co-developed by and operated with Sumitomo Pharma, which owns Enzyvant’s immediate parent company, Sumitovant Biopharma.

“We’re excited that this new site not only expands the range and scope of our manufacturing offerings, but also builds our presence in Research Triangle Park – leveraging our existing employee base and support the local area with new hires,” said Larry Weiner, VP of Pharmaceutical Development & Manufacturing at Enzyvant.